CA2493282A1 - Methode et composition destinees a inhiber la proliferation de cellules cancereuses a l'aide de l'urease et de composes anti-cancereux faiblement basiques - Google Patents

Methode et composition destinees a inhiber la proliferation de cellules cancereuses a l'aide de l'urease et de composes anti-cancereux faiblement basiques Download PDF

Info

Publication number
CA2493282A1
CA2493282A1 CA002493282A CA2493282A CA2493282A1 CA 2493282 A1 CA2493282 A1 CA 2493282A1 CA 002493282 A CA002493282 A CA 002493282A CA 2493282 A CA2493282 A CA 2493282A CA 2493282 A1 CA2493282 A1 CA 2493282A1
Authority
CA
Canada
Prior art keywords
urease
cancer
cells
composition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002493282A
Other languages
English (en)
Other versions
CA2493282C (fr
Inventor
Donald Segal
Jerry Mcelroy
Heman Chao
Wah Y. Wong
John Docherty
Jodi Dickstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helix Biopharma Corp
Original Assignee
Helix Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Biopharma Corp filed Critical Helix Biopharma Corp
Priority to CA2493282A priority Critical patent/CA2493282C/fr
Publication of CA2493282A1 publication Critical patent/CA2493282A1/fr
Application granted granted Critical
Publication of CA2493282C publication Critical patent/CA2493282C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2493282A 2005-01-31 2005-01-31 Methode et composition destinees a inhiber la proliferation de cellules cancereuses a l'aide de l'urease et de composes anti-cancereux faiblement basiques Active CA2493282C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2493282A CA2493282C (fr) 2005-01-31 2005-01-31 Methode et composition destinees a inhiber la proliferation de cellules cancereuses a l'aide de l'urease et de composes anti-cancereux faiblement basiques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2493282A CA2493282C (fr) 2005-01-31 2005-01-31 Methode et composition destinees a inhiber la proliferation de cellules cancereuses a l'aide de l'urease et de composes anti-cancereux faiblement basiques

Publications (2)

Publication Number Publication Date
CA2493282A1 true CA2493282A1 (fr) 2006-07-31
CA2493282C CA2493282C (fr) 2020-05-12

Family

ID=36764070

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2493282A Active CA2493282C (fr) 2005-01-31 2005-01-31 Methode et composition destinees a inhiber la proliferation de cellules cancereuses a l'aide de l'urease et de composes anti-cancereux faiblement basiques

Country Status (1)

Country Link
CA (1) CA2493282C (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640806B2 (en) 2016-09-24 2020-05-05 Helix Biopharma Corp. Restoring function of tumour acidified T cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640806B2 (en) 2016-09-24 2020-05-05 Helix Biopharma Corp. Restoring function of tumour acidified T cells

Also Published As

Publication number Publication date
CA2493282C (fr) 2020-05-12

Similar Documents

Publication Publication Date Title
AU2015252518B2 (en) New stable antibody-drug conjugate, preparation method therefor, and use thereof
EP3261678B1 (fr) Conjugués anticorps-uréase pour des fins thérapeutiques
IL166249A (en) Use of urease enzyme for the preparation of medicaments for inhibiting cancer cell growth
US20230125881A1 (en) Novel polypeptides and uses thereof
JP2022541650A (ja) ペプチド核酸系の作用物質を用いて癌を治療するための方法および組成物
US7264800B2 (en) Method and composition for inhibiting cancer cell growth
CA2493282C (fr) Methode et composition destinees a inhiber la proliferation de cellules cancereuses a l&#39;aide de l&#39;urease et de composes anti-cancereux faiblement basiques
US11752215B2 (en) Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties
Joshi et al. Transferrin Receptor and Targeting Strategies
KR102387320B1 (ko) 약물 반응성 예측을 위한 대장암 진단 또는 검출용 조성물, 대장암 예방 또는 치료용 조성물
US6696064B2 (en) Methods of protecting vasculature from damage by diphtheria toxin-and pseudomonas toxin-based immunotoxins during therapy

Legal Events

Date Code Title Description
EEER Examination request